A Study of LY900027 Given by Insulin Pump to Participants With Type 1 Diabetes Mellitus

• Status: Completed
• Trial end date: 2020-07-14
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to learn more about a new formulation of insulin lispro when given by an insulin pump to participants with type 1 diabetes mellitus. The study will investigate how the body processes the drug and how the drug affects the body. Information about side effects will be collected. The study will last from six to 12 weeks for each participant.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Insulin; Insulin Lispro; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Diagnosis of T1DM for at least 1 year

• Fasting C-peptide ≤0.30 nanomoles per liter (nmol/L)

• Bbody mass index between 18.5 and 33.0 kilograms per square meter (kg/m²)

• Participants should have a glycated hemoglobin of ≤9.0% at screening

Exclusion Criteria: